CME Presentations




  • Jürgen Floege, MD

    Jürgen Floege, MD

    Jürgen Floege, MD

    Head of the Division, Nephrology and Immunology

    Jürgen Floege, MD, is head of the Division of Nephrology and Immunology at the University of Aachen, Germany since 1999. Dr. Floege is a former executive council member of the International Society of Nephrology (ISN), the European Renal Association (ERA-EDTA), and currently coordinates the KDIGO glomerular disease management guidelines. His research interests encompass both basic research like studies underlying progression of renal disease in particular renal fibrosis as well as clinical research in immune-mediated renal disease, bone and mineral disorders (CKD-MBD), and cardiovascular disease in uremic patients. Furthermore, Dr. Floege is a Distinguished Fellow of the ERA-EDTA and recipient of the 2018 ERA-EDTA Award for Outstanding Clinical Contributions to Nephrology.
  • Michelle O’Shaughnessy, MD

    Michelle O’Shaughnessy, MD

    Michelle O’Shaughnessy, MD

    Consultant Nephrologist

    Michelle O’Shaughnessy, MB BCh BAO MS MD, is a Consultant Nephrologist at University Hospital Galway, Ireland. She is a Fellow of the American Society of Nephrology, Fellow of the Royal College of Physicians of Ireland, and member of the KDIGO Executive Committee. She has a clinical and academic subspecialist interest in glomerular diseases and has published over 50 peer-reviewed scientific manuscripts predominantly focusing on glomerular disease epidemiology and clinical outcomes. Current research funding from the Health Research Board (Ireland) and Irish Kidney Association supports research examining patient-reported outcomes in patients with glomerular disease. She is also establishing University Hospital Galway as a site for clinical trials in glomerular diseases, including IgA nephropathy.

CME Information

Global LogoPQH Logo

Beyond RAS Inhibition for IgAN: Guideline-directed Treatment and Emerging Therapies to Achieve Proteinuria Goals and Preserve Kidney Function

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Kidney Disease Improving Global Outcomes (KDIGO)


This activity is supported by an educational grant from Travere Therapeutics, Inc.


August 15th, 2023, from 12:00pm-1:00pmET


The intended audience for this activity is nephrologists/pediatric nephrologists, kidney transplant surgeons, and specialty NP/PAs.


An improved understanding of the etiology of immunoglobulin A nephropathy (IgAN) has led to the development of new targeted treatments that address the pathophysiology responsible for podocyte injury and further reduce proteinuria. Some may also have the advantage of reducing treatment burden. Unfortunately, most patients with IgAN are diagnosed late in the disease course when irreversible kidney damage has already occurred.

To help realize the potential of new and emerging agents, join an expert panel of nephrologists to discover how to recognize IgAN early. Panelists will discuss the limitations of traditional treatments and explore evidence on the efficacy, safety, and role of new and emerging options. Experts will also provide strategies for engaging patients and caregivers in effective shared decision-making.

Do you have patients at risk for IgAN who need to be able to recognize the signs and symptoms of the disease? Or do you have patients with IgAN who could use education on effective treatments? Direct your patients to to access the activity, “Knowledge Is Power: The Information You Need to Recognize Your Risk and Early Signs of Kidney Disease and Take Action to Optimize Your Treatment.”


After completing this activity, the participant should be better able to:
  • Recognize the clinical presentation of IgAN in the early stages
  • Identify required tests to confirm a diagnosis of IgAN
  • Determine the place in the current armamentarium of new and emerging treatments for IgAN based on clinical trial design and data, with a focus on agents that provide dual endothelin type A and angiotensin II subtype 1 receptor inhibition
  • Explain how dual endothelin type A and angiotensin II subtype 1 receptor inhibition reduce proteinuria more than RAS inhibition alone


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Michelle O'Shaughnessy, MB BCh, MD, MS, FASN, FRCPI
Consultant Nephrologist
Galway University Hospitals
Consulting Fee (e.g., Advisory Board): Vera therapeutics, Chinook therapeutics, Otsuka pharmaceuticals
Honoraria: Vifor pharma
Jürgen Floege, MD
Professor of Medicine
Division of Nephrology and Rheumatology
RWTH Aachen University Hospital
Honoraria: AstraZeneca, Bayer, Boehringer, Calliditas, Chinook, Novartis, Omeros, Stadapharm, Travere, Vifor

The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at